Abstract: A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 orin an amino acid sequence having at least 60% homology thereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrate binding site; at least one amino acid modification in the N-terminus; at least one amino acid modification at position 76; or at least one amino acid modification at position 44 or 89. The modified lectin protein does not consist of the amino acid sequence of any of SEQ ID NOs: 2 to 4.

Abstract: A method of examining a possibility of a subject having pancreatic cancer, including measuring GPRC5C (G protein-coupled receptor family C group 5 member C) present in an exosome in a specimen collected from the subject.

Abstract: The field of the DISCLOSURE lies in active materials for organic image sensors. The present disclosure relates to transparent N materials and/or to transparent P materials and their use in absorption layer(s), photoelectric conversion layer(s) and/or an organic image sensor and methods for their synthesis. The present disclosure also relates to photoelectric conversion layer(s) including an active material according to the present disclosure, to a device, including active material(s) according to the present disclosure or photoelectric conversion layer(s) according to the present disclosure. Moreover, the present disclosure relates to an organic image sensor including photoelectric conversion layer(s) according to the present disclosure.

Abstract: A number of variations may include a sterile kit that may include a tray constructed and arranged to hold the necessary items to access an Ommaya reservoir and the tray may define a plurality of other resources or indentations constructed and arranged to seat, hold, or house additional components of the sterile kit. The sterile kit may additionally include a paper towel, a fenestrated drape, a plurality of sponge applicators, at least one pouch of povidone-iodine, at least one retractable winged butterfly needle, at least one luer lock syringe, a 3-way stopcock, a plurality of collection vials with tops which may be screwed on to prevent the contents thereof from leaking or escaping, sterile pads, bandages including adhesive bandages, and other components.

Abstract: A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI).

Abstract: The present invention relates to a polypeptide comprising a Gram negative endolysin and a peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a sushi peptide or a defensin, wherein the endolysin in turn is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and sequences having at least 80% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and/or SEQ ID NO:9. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body.

Abstract: A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.

Abstract: The present invention relates to an epitope of a thioredoxin-1 (Trx1) antigen and a use thereof, and more particularly, to the epitope, and an antibody or an antigen-binding fragment binding thereto. The epitope region of the human Trx1 antigen confirmed in the present invention may be effectively used in the development of an improved antibody to enhance the binding affinity of an anti-Trx1 antibody. In addition, the improved antibody of the present invention is effective in improvement of performance of a breast cancer diagnosis kit due to excellent binding affinity for Trx1 and very high sensitivity and specificity, compared to a conventional anti-Trx1 antibody. Further, the accuracy and reliability of breast cancer diagnosis may significantly increase because exceptionally high sensitivity and specificity are exhibited by detecting the monoclonal antibody of the present invention, which specifically binds to Trx1, rather than detecting CA15-3, another conventional breast cancer diagnostic biomarker.

Abstract: The present disclosure relates to an antibody specifically binding to bovine pregnancy-associated glycoprotein 1 (bPAG1) or an antigen-binding fragment thereof. The present disclosure further relates to a hybridoma cell producing the antibody; a composition including the antibody as an effective ingredient for diagnosis of bovine pregnancy; and a kit for diagnosis of bovine pregnancy. The present disclosure also relates to a method of diagnosing bovine pregnancy. Binding specifically to bPAG1, which is a pregnancy-associated plasma protein in bovines, the antibody allows a simple diagnosis of pregnancy in animals such as bovines of which the reproduction is important, so that the antibody may be usefully applied in the livestock industry by increasing reproduction efficiency.

Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.

Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

Abstract: A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

Abstract: The method of analyzing absorbance of one or more liquid samples (3) arranged in the wells (2) of a microplate (1) comprises the steps of setting a desired wavelength falling within the wavelength range of 380 nm-750 nm for absorbance measurement (101), illuminating the samples (3) using electromagnetic radiation having a bandwidth of at most 20 nm around the set wavelength (102), measuring radiant flux transmitted through each sample (3) (103), on the basis of measured radiant flux values, determining an absorbance value for each sample (3) (104), and visualizing the absorbance values on a display (12) as a matrix comprising a plurality of cells (23), each cell (23) corresponding to a well (2) of the microplate (1) (105). The set wavelength is used as an input for determining the visual properties of the cells (23).

Abstract: A device for detecting particles in air; said device comprising: a receiver for receiving a flow of air comprising particles; a particle capturing arrangement configured to transfer the particles from the flow of air to a liquid for collection of a set of particles in the liquid; a flow channel configured to pass a flow of the liquid comprising the set of particles through the flow channel; a light source configured to illuminate the set of particles in the flow channel, such that an interference pattern is formed by interference between light being scattered by the set of particles and non-scattered light from the light source; and an image sensor comprising a plurality of photo-sensitive elements configured to detect incident light, the image sensor being configured to detect the interference pattern.

Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

Abstract: A system is provided for identifying the presence of a target molecule or ion. The system comprises a solid support, and at least one chemical reagent applied to the solid support. Each chemical reagent produces a presumptive color indication that identifies or excludes the presence of a target molecule or ion.

Abstract: Aspects of the disclosure include a system for performing cytometry that can be operated in three operational modes. In one operational mode, a fluorescence image of a sample is obtained by exciting one or more fluorophore(s) with a top-hat-shaped excitation beam with a plurality of beams that are radiofrequency shifted relative to one another. In another operational mode, a sample can be illuminated successively over a time interval by a laser beam at a plurality of excitation frequencies in a scanning fashion to generate an image of the sample from the detected fluorescence. In another operational mode, the system can be operated to illuminate a plurality of locations of a sample concurrently by a single excitation frequency (e.g., a horizontal extent), which is generated, e.g., by shifting the central frequency of a laser beam by a radiofrequency and detected fluorescence is used to analyze the sample.

Abstract: The present disclosure relates to a proximity sensor. The proximity sensor includes: a light emitter (for example, a vertical cavity surface emitting LASER (VCSEL)) configured to irradiate light to a target to be inspected; a first light receiver having a first crosstalk characteristic, configured to detect an external reflected light from a target to be inspected within a first detection region (for example, 0˜5 cm approximately); and a second light receiver having a second crosstalk characteristic different from the first crosstalk characteristic, configured to detect an external reflected light from a target to be inspected within a second detection region (for example, 3˜60 cm approximately) relatively further than the first detection region.

Abstract: In accordance with one aspect of the presently disclosed inventive concepts, a metal aerogel includes a plurality of metal nanowires formed into a porous three-dimensional structure, where pores in the structure are anisotropic.

Abstract: Methods, devices, and systems for performing digital assays are provided. In certain aspects, the methods, devices, and systems can be used for the amplification and detection of nucleic acids. In certain aspects, the methods, devices, and systems can be used for the recognition, detection, and sizing of droplets in a volume. Also provided are compositions and kits suitable for use with the methods and devices of the present disclosure.

Abstract: Provided herein are methods, compositions, and kits for assays, many of which involve amplification reactions such as digital PCR or droplet digital PCR. The assays may be used for such applications as sequencing, copy number variation analysis, and others. In some cases, the assays involve subdividing a sample into multiple partitions (e.g., droplets) and merging the partitions with other partitions that comprise adaptors with barcodes.

Abstract: The present disclosure provides, among other things, compositions (e.g., autoantibodies) that inhibit the growth, viability, or mobility of (invasion by) a cancer cell. Also provided are applications, such as therapeutic and diagnostic methods, in which the agents are useful, as well as screening methods for identifying autoantibodies useful in the applications.

Abstract: As with many human physiological systems, issues within the central nervous system can arise for individuals leading to a variety of neurological disorders including, but not limited to, Charcot-Marie-Tooth disease, Alzheimer' disease, Parkinson's disease, multiple sclerosis, myasthenia gravis, demyelination, and axonal degeneration. However, culture devices presently provide researchers with limitations in their research. Embodiments of the invention aims to address these various limitations and allow studies, methods and screenings which cannot be performed with prior art culture devices. These include reducing manufacturing complexity, volumes of pharmaceuticals and cells required, allowing use in fields other than neurobiology, improved adhesion within the desired micro-channel regions of the devices, and increasing cell survival in cultures.

Abstract: The present disclosure provides, inter alia, compositions and methods for enforcing a pattern of cell surface fucosylated lactosaminyl glycans on a human cell. In certain embodiments, the compositions and/or methods utilize one or more members of the ?(1,3)-fucosyltransferase family. In certain embodiments, a process for custom-modifying a fucosylated lactosaminyl glycan on a human cell is disclosed.

Abstract: Disclosed herein are systems and methods of estimating the autofluorescence (AF) signal and other non-target signals in each channel of a multi-channel image of a biological sample that is stained with one or more fluorescent labels. In some embodiments, the estimated autofluorescence signal can then be subtracted or masked from the multi-channel image. In some embodiments, the autofluorescence-removed multichannel image can then be use for further processing (e.g. image analysis, etc.).

Abstract: The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (42), a pump (64) and a plurality of valves (1-11) configured to at least partially control fluid flow through a fluid circuitry and a separation column (40) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

Abstract: Devices for magnetic 3d culture are described including magnetic lids/bases for single Petri plates and adjustable height cap for same. Similar devices for multi-magnet culture plates wherein multiwell plates have all adjacent magnets orientated in the opposite polarity, and methods of making same.

Abstract: Embodiments of the present invention relate to a combination of experimental and computational workflows that allow characterization of skin and subcutaneous tissue microbial flora and its associated metabolome, aiming to first evaluate an individual's skin and subcutaneous tissue to determine if any skin condition is as a result of an imbalance or absence of commensal or mutualistic microorganisms or their associated metabolites. In particular, embodiments of the methods and the associated computational platform provided herein relate to conducting a customized or personalized test and obtaining customized or personalized information regarding the skin and subcutaneous tissue flora and its associated metabolome there from. This may be accomplished by simultaneously identifying hundreds of microorganisms or metabolites on an individual's skin and subcutaneous tissue and comparing the resulting profile to a previously compiled healthy profile from our database of skin profiles.

Abstract: Embodiments of apparatuses and methods for determining a positioning of sensors in a wound dressing are disclosed. In some embodiments, a wound monitoring and/or therapy system can include a wound dressing and a plurality of sensors configured to measure one or more wound characteristics. The wound monitor system can also include at least one positioning device configured to indicate position and/or orientation in the wound of a sensor of the plurality of sensors. In some embodiments, a detector can be configured to determine, based on the positioning data, the position and/or orientation in the wound of the sensor of the plurality of sensors. In some embodiments, the plurality of sensors can be positioned on a strip or string of material in communication with the positioning device.

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.

Abstract: A system for one-sided measuring a presence of magnetic particles in a probe volume comprises a one-sided coil assembly and a current controller, wherein the one-sided coil assembly is arranged around a central coil assembly axis for generating a rotating magnetic field distribution and comprises at least 3, preferably at least 4, circumferentially distributed coil assembly sectors, wherein the current controller is configured to generate a time varying current in each of said coil assembly sectors, said time varying current comprising a periodic modulation with a rotation frequency and phase shifted between adjacent coil assembly sectors to generate a magnetic field rotating in a plane perpendicular to the coil assembly axis, said magnetic field rotating with a rotation frequency associated with a frequency of said periodic modulation, and wherein the system is configured for measuring said presence of magnetic particles in said probe volume with said one-sided coil assembly.

Abstract: This disclosure generally relates to systems and methods for facilitating determination of morphology (e.g., shape) and structure (e.g., size, rigidity) and/or penetrating channels (e.g., microchannels) of occlusions (e.g., clots, fluid obstructions, tumors, chronic total occlusions) involving magnetic particles (e.g., nanoparticles, microparticles) controlled by an external magnetic control system.

Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

Abstract: This disclosure provides oligomers, combinations of oligomers, compositions, kits, uses, and methods for detecting a C1orf43 nucleic acid, such as C1orf43 mRNA, such as human C1orf43 mRNA, in a sample.

Abstract: Disclosed is an assay device which comprises a liquid sample addition zone, a reagent zone, a detection zone, and a wicking zone, all defining a fluid flow path. The device further comprises a reagent addition zone along and in fluid communication with the fluid flow path downstream of the sample addition zone and upstream of the detection zone. An interrupting wash is added at this reagent addition zone in accordance with the method of the subject invention to control sample volume. The interrupting wash fluid is added at a predetermined fill volume on the chip device and also serves to wash the detection channel and fill the remaining chip volume.

Abstract: Methods and compositions for treating cancer, e.g., prostate cancer, using a combination of P-Rex1 or Rac1 inhibitors and VEGF/VEGFR-targeted therapy.

Abstract: Exemplified methods and systems facilitate presentation of data derived from measurements of endotoxins in fluid samples. In particular, the exemplified methods and systems facilitate presentation of such measurements in a graphical user interface and/or in a report for endotoxin concentrations in a fluid sample. The presentation facilitates a unified and intuitive graphic visualization that are presented within a single interactive interface and/or report.

Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

Abstract: Provided herein are high throughput methods for measuring the protease activity of the complement C3 convertase by detecting the consumption of C3 or the production of C3a in vivo and in vitro.

Abstract: Provided herein are compositions and methods for detecting the binding of a peptide to an MHC molecule, and the binding of a peptide:MHC complex to a TCR. In preferred embodiments, the compositions and methods are in a highly-multiplexed way. The compositions and methods disclosed herein can be used to provide direct information on which peptides are bound to an MHC molecule. Also provided is a method for simultaneously detecting a large number of peptides for binding to an MHC molecule and/or a T cell. A method for detecting competitive binding of a large number of peptides to an MHC molecule and/or a T cell is also disclosed. Also provided herein is a method for simultaneously detecting a large number of specific TCRs. The compositions and methods of the present invention are useful for vaccine design, research and monitoring of autoimmune and infectious disease, immunogenicity testing of therapeutics, and tissue typing.

Abstract: The present subject matter provides urea biosensors as well as compositions, devices, and methods comprising such biosensors.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The present embodiments relate generally to a system for improved storage of electronic health information, the system including: a computing device for receiving the electronic health information; and a server for communicating with the computing device, the server being accessible by the computing device at a first network location. The server can be configured to: receive a request from the computing device for a second network location, the second network location usable for storing the electronic health information, and the second network location being different from the first network location; determine the second network location; and provide the second network location to the computing device; and the computing device stores the electronic health information at the second network location.

Abstract: The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.

Abstract: Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.

Abstract: The present teachings provide apparatuses and methods for automated handling of samples, e.g., biological or chemical samples. The apparatuses and the methods of the present teachings allow automated performance of various sample manipulation steps without manual intervention. In a preferred embodiment, the present teachings provide apparatuses and methods for automated enrichment of templated beads produced by PCR.

Abstract: Methods of detecting ZNT8 antibodies in serum are described. The methods include proteoliposomes comprising a transmembrane domain (TMD) and a cytosolic domain (CTD) of ZnT8 proteins exposed on the exterior of the proteoliposome; serum comprising antibodies targeting the ZnT8 proteins; and labelled captured autoantibodies that bind to ZnT8 antibodies.